The Application of a Novel Urinalysis System (UF-5000) for Reducing Unnecessary Antibiotic Use in Clinical Suspected UTI Patients
Launched by THE UNIVERSITY OF HONG KONG · Apr 1, 2025
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new urine testing system called the UF-5000 to help safely diagnose urinary tract infections (UTIs) and reduce unnecessary antibiotic use. UTIs are common, but many people are treated with antibiotics even when they don’t have an infection, which can lead to antibiotic resistance—making it harder to treat infections in the future. The UF-5000 provides quick and accurate information about the bacteria in urine samples, allowing doctors to determine if antibiotics are truly needed. Unlike traditional urine tests that can take several days, results from the UF-5000 are available in just 5 minutes.
To participate in this trial, you must be an adult who thinks they might have a lower urinary tract issue and be willing to give consent. However, if you have certain conditions, like a known sexually transmitted disease or have taken antibiotics recently, you may not be eligible. If you join the study, you can expect to provide a urine sample that will be tested with the UF-5000, helping doctors make better decisions about your treatment based on accurate information. This approach aims to ensure that antibiotics are only given when truly necessary, ultimately helping to combat antibiotic resistance.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adult patients who are suspected to have LUTs in outpatient clinic.
- • 2. Willing to consent to participate the trial.
- • 3. Be able to understand the nature of the study.
- Exclusion Criteria:
- • 1. Any suspected or known sexual transmitted diseases. (Such as gonorrhea, etc.)
- • 2. Use of any systematic antibiotics or antiviral treatment within two weeks
- • 3. With evidence of systematic infection including high fever, significantly increase of blood white blood cell count, etc.
- • 4. Known or suspected allergic history/adverse drug reactions to any antibiotics
- • 5. With previous history of multidrug resistant (MDR) bacterial infection.
- • 6. Any medical history that indicates the need of immediate antibiotics treatment, such as chronic conditions and/or taking immunosuppressants.
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported